About: The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection
Creator	Baoying, Huang Chuan, Qin Jiaming, Lan Jinghua, Yan Linlin, Bao Wenjie, Tan Yanfeng, Yao Yao, Deng Yawei, Hu Gao, George
Source	Elsevier; Medline; PMC
abstract	Abstract The persistent public health threat of infection with the Middle East respiratory syndrome coronavirus (MERS-CoV) highlights the need for an effective MERS-CoV vaccine. Previous studies have focused mainly on the receptor-binding domain (RBD) on the spike protein of MERS-CoV. Herein, we investigated the immunogenicity and protective potential of the recombinant N-terminal domain (rNTD) of spike proteins as a vaccine candidate. BALB/c mice vaccinated with 5 or 10μg of rNTD protein demonstrated a significant humoral immune response (serum IgG and neutralizing activity). Additionally, according to the enzyme-linked immunospot, intracellular cytokine staining, and cytometric bead array assays, significant and functional T-cell immunity was induced by 10μg of the rNTD vaccination with aluminum and CpG adjuvant. Furthermore, rNTD-immunized mice showed reduced lung abnormalities in a MERS-CoV-challenge mouse model transfected with an adenoviral vector expressing human DPP4, showing protection consistent with that found with rRBD vaccination. These data show that rNTD induced potent cellular immunity and antigen-specific neutralizing antibodies in mice and that it demonstrated protective capacity against a viral challenge, indicating that rNTD is a vaccine candidate against MERS-CoV infection.
has issue date	2017-01-03(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2016.11.064
bibo:pmid	27899228
has license	els-covid
sha1sum (hex)	d0c8e2e83670f588fa1673bb2234b520aa4f8242
schema:url	https://doi.org/10.1016/j.vaccine.2016.11.064
resource representing a document's title	The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection
has PubMed Central identifier	PMC7115548
has PubMed identifier	27899228
schema:publication	Vaccine
resource representing a document's body	covid:d0c8e2e83670f588fa1673bb2234b520aa4f8242#body_text
is schema:about of	named entity 'MERS-CoV' named entity 'investigated' named entity 'vaccine' named entity 'proteins' named entity 'infection' named entity 'MERS-CoV' named entity 'ARRAY' named entity 'EFFECTIVE' named entity 'ADENOVIRAL VECTOR' named entity 'CAPACITY' named entity 'VACCINE CANDIDATE' named entity 'INTRACELLULAR CYTOKINE STAINING' named entity 'IGG' named entity 'FUNCTIONAL' named entity 'PREVIOUS' named entity 'PROTECTION' named entity 'N-TERMINAL ' named entity 'SIGNIFICANT' named entity 'ENZYME' named entity 'CONSISTENT WITH' named entity 'SPIKE PROTEIN' named entity 'RECEPTOR' named entity 'SPIKE' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'MOUSE MODEL' named entity 'CELLULAR IMMUNITY' named entity 'ANTIGEN' named entity 'ACTIVITY' named entity 'DOMAIN' named entity 'NEUTRALIZING ANTIBODIES' named entity 'HUMAN' named entity 'ALUMINUM' named entity 'VIRAL' covid:arg/d0c8e2e83670f588fa1673bb2234b520aa4f8242 named entity 'SPIKE' named entity 'VACCINE' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'POTENTIAL' named entity 'ADJUVANT' named entity 'DEMONSTRATED' named entity 'BINDING' named entity 'FOUND' named entity 'RECOMBINANT' named entity 'RECOMBINANT' named entity 'IS A' named entity 'N-TERMINAL ' named entity 'CHALLENGE' named entity 'IMMUNOGENICITY' named entity 'THREAT' named entity 'REDUCED' named entity 'BALB' named entity 'PUBLIC HEALTH' named entity 'IMMUNITY' named entity 'PROTEINS' named entity 'PROTEIN ' named entity 'HUMORAL IMMUNE RESPONSE' named entity 'STUDIES' named entity 'SPECIFIC' named entity 'INDUCED' named entity 'VACCINATED' named entity 'INFECTION' named entity 'PERSISTENT' named entity 'CPG' named entity 'MICE' named entity 'IMMUNIZED' named entity 'VACCINE' named entity 'FOCUSED' named entity 'MERS' named entity 'NEED FOR' named entity 'DATA' named entity 'IS A' named entity 'DPP4'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software